Recombinant Human HLA-B*07:02&B2M&HPV16 E7(KPTLKEYVL) Monomer Protein (HEK293)，Avi & His

The study of the HLA-B*07:02, beta-2-microglobulin (B2M), and HPV16 E7 (KPTLKEYVL) monomer recombinant protein is significant in the field of immunology and cancer research. Human Papillomavirus (HPV), particularly HPV16, is a well-established etiological agent of cervical and other anogenital cancers. The E7 oncoprotein of HPV16 plays a crucial role in cell transformation and proliferation by interacting with host cell proteins. HLA-B*07:02 is a major histocompatibility complex (MHC) class I molecule that presents endogenous peptides, including viral antigens, to CD8+ cytotoxic T lymphocytes. The specific peptide KPTLKEYVL, derived from the E7 protein, is known to be a potent T-cell epitope that elicits immune responses in HPV-infected individuals. By creating a recombinant protein that includes HLA-B*07:02, B2M, and the HPV16 E7 peptide, researchers aim to investigate the structure and function of this complex, assess its stability, and understand how it interacts with T-cell receptors. This research has implications for developing targeted immunotherapies and vaccines that could enhance anti-viral and anti-tumor immunity in patients with HPV-associated malignancies. Understanding how this monomeric protein functions at a molecular level can contribute to improved strategies for diagnosing, treating, and preventing HPV-related diseases.